Phreesia (NYSE:PHR) Stock Rating Upgraded by DA Davidson

Phreesia (NYSE:PHR) was upgraded by stock analysts at DA Davidson to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

PHR has been the subject of several other research reports. Mizuho started coverage on shares of Phreesia in a report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price for the company. KeyCorp boosted their price target on shares of Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Stephens reaffirmed an “overweight” rating and set a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. Needham & Company LLC boosted their target price on Phreesia from $29.00 to $35.00 and gave the company a “buy” rating in a report on Friday, September 5th. Finally, Wall Street Zen raised Phreesia from a “hold” rating to a “buy” rating in a research report on Sunday, June 1st. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $34.08.

Phreesia Trading Down 1.0%

PHR opened at $26.51 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. Phreesia has a one year low of $17.07 and a one year high of $32.76. The company has a market cap of $1.58 billion, a P/E ratio of -63.12 and a beta of 0.72. The business’s 50-day simple moving average is $28.27 and its 200-day simple moving average is $26.50.

Phreesia (NYSE:PHR) last posted its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. The firm had revenue of $117.26 million during the quarter, compared to analysts’ expectations of $116.39 million. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The firm’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. As a group, equities research analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Activity

In other Phreesia news, SVP David Linetsky sold 23,729 shares of Phreesia stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $28.50, for a total value of $676,276.50. Following the transaction, the senior vice president directly owned 193,510 shares in the company, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the business’s stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the transaction, the director directly owned 22,037 shares in the company, valued at approximately $609,763.79. The trade was a 11.28% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,292 shares of company stock valued at $3,295,323. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. Loomis Sayles & Co. L P purchased a new position in Phreesia in the second quarter valued at about $34,162,000. American Century Companies Inc. lifted its position in shares of Phreesia by 3,741.9% during the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock valued at $25,137,000 after acquiring an additional 957,842 shares during the period. Nuveen LLC acquired a new stake in shares of Phreesia during the 1st quarter valued at approximately $14,206,000. Finally, Champlain Investment Partners LLC boosted its stake in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock worth $75,312,000 after acquiring an additional 490,340 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.